NCT03419572 (CASSIOPE) is a clinical trial of Data collection in Renal Cell Carcinoma, sponsored by Ipsen.

Who is sponsoring NCT03419572?

NCT03419572 is sponsored by Ipsen.

What drugs are being tested in NCT03419572?

Interventions in NCT03419572: Data collection.

What condition does NCT03419572 study?

NCT03419572 studies Renal Cell Carcinoma.

Is NCT03419572 still recruiting?

NCT03419572 is currently completed. Last updated 15 August 2022.

Last reviewed 2022-08-15 · How we verify

NCT03419572: CASSIOPE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma

Completed Last updated 15 August 2022

What this trial tests

trial testing Data collection in Renal Cell Carcinoma in 689 participants. Completed in 19 May 2022.

Timeline

24 April 2018

Primary endpoint
19 May 2022

19 May 2022

Quick facts

Lead sponsor	Ipsen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	689
Start date	24 April 2018
Primary completion	19 May 2022
Estimated completion	19 May 2022
Sites	91 locations across France, Italy, Netherlands, Greece, Belgium, Austria, United Kingdom, Germany

Drugs / interventions tested

Data collection — full drug profile →

Conditions studied

Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →

Sponsor

Ipsen — full company profile →

Who can join

18 and older, any sex, with Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (RCC) following prior VEGF-targeted therapy in real life settings in terms of dose modifications due to adverse events (AEs) when used as a second line therapy or third and later line therapy. Other patterns of use of cabozantinib will also be described.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies.
Xu F, Liu Y, Que Z, Luo B, et al · · 2025 · cited 3× · PMID 40135802 · DOI 10.1002/advs.202409293
A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE).
Staehler M, Basso U, Eymard JC, Barthelemy P, et al · · 2025 · PMID 39740313 · DOI 10.1016/j.clgc.2024.102285
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology
· 2022

Verify or expand the search:

Other trials of Data collection

Trials testing the same drug.

NCT07010562 — A Multi-site, Pre-clinical, Prospective Data Collection Study in Patients Undergoing a Right Heart Catheterization · not yet recruiting
NCT07418359 — Comparison of Patient's Physical Activity Levels According to the Physical Activity Level of Their General Practitioner · recruiting
NCT07197398 — Preoperative Data and the Spinal Spread of Local Anesthetic in Cesarean Section · recruiting
NCT06998797 — Efficacy of Subcutaneous Infliximab in Acute Severe Ulcerative Colitis: a Multicenter Retrospective Study · not yet recruiting
NCT07529730 — Outcomes of Surgical Treatment in Patients With Infective Endocarditis · completed

Other recruiting trials for Renal Cell Carcinoma

Currently open trials in the same condition.

NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
NCT07195682 — A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07227402 — A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6 · Phase 3 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting

Other Ipsen trials

Trials by the same sponsor.

NCT07387549 — A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis · Phase 3 · not yet recruiting
NCT07497724 — Retrospective Observational Study of Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-P · not yet recruiting
NCT07427797 — A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between · Phase 3 · recruiting
NCT07435428 — A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Line · Phase 3 · recruiting
NCT07441707 — A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03419572 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ipsen
Last refreshed: 15 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03419572.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing